New algorithm for gene testing in metastatic prostate cancer using liquid biopsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on implementing a novel algorithm for testing HRR gene mutations in patients with metastatic prostate cancer (mPC) by integrating liquid biopsy techniques. It involves analyzing the current clinical landscape in Italy to identify gaps in testing and treatment. The methodology includes patient enrollment, blood sample collection, plasma purification, ctDNA extraction, and next-generation sequencing (NGS) analysis of HRR genes. The goal is to develop a testing algorithm based on real-world data and molecular analysis, ultimately creating a best practice model for diagnostic procedures in mPC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.

Exclusion Criteria:

* Unable to provide written informed consent

Where it's running

• European Institute of oncology
  Milan, Italy, Italy Recruiting

Study contacts

• Study coordinator: Elena Guerini Rocco, MD
• Email: elena.guerinirocco@ieo.it
• Phone: 00390294372871

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry collecting data on advanced prostate cancer imaging

  This study is collecting information on how advanced imaging techniques for prostate cancer can help doctors make better treatment decisions and improve patient outcomes.

  Recruiting at 4 sites Fundacio Puigvert · Leuven and 23 other locations · NCT06866782

• Understanding what patients want from NSCLC treatment monitoring

  Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.

  Recruiting European Institute of Oncology · Milan, mI · NCT07909343

• Single-Port Robotic Lobectomy for Early-Stage NSCLC

  This study tests the safety and outcomes of using the da Vinci Single-Port system for lobectomy and lymph node dissection in people with early-stage non-small cell lung cancer.

  Recruiting European Institute of Oncology · Milan, Mi · NCT07790406

• Disparities in Mental Health Screening and Support for Cancer Patients and Families

  This study tests whether cancer patients and their families across Europe have equal access to mental health screening and support services.

  Recruiting European Institute of Oncology · Milan, Mi · NCT07691281

• Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Systemic Therapy

  This study looks at how stereotactic radiosurgery for melanoma brain metastases works when patients are also receiving immunotherapy or targeted therapy.

  Recruiting at 2 sites European Institute of Oncology · Milan, Italy and 1 other locations · NCT07691255

• Predictive biomarkers for immunotherapy in endometrial cancer

  This study tests molecular and epigenetic features to see if they can predict which endometrial cancer patients will respond to immune checkpoint inhibitors.

  Recruiting European Institute of Oncology · Milan, Italy · NCT07690540

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.